News · 26 weeks66+267%
2026-03-012026-08-23
Mix2890d
- Insider16(57%)
- Other4(14%)
- Analyst4(14%)
- Earnings2(7%)
- SEC Filings2(7%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on Tandem Diabetes CareWilliam Blair initiated coverage of Tandem Diabetes Care with a rating of Outperform
- INSIDEREVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 4,120 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 5% to 52,040 units (SEC Form 4) to satisfy withholding tax4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERPRESIDENT & CEO Sheridan John F converted options into 15,916 shares and covered exercise/tax liability with 8,099 shares, increasing direct ownership by 5% to 160,260 units (SEC Form 4) (for withholding tax)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 3,014 shares and covered exercise/tax liability with 1,618 shares (SEC Form 4) to satisfy withholding tax4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Admin. Officer Morrison Susan converted options into 2,827 shares and covered exercise/tax liability with 809 shares, increasing direct ownership by 4% to 52,788 units (SEC Form 4) (tax withholding)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 1,010 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 30,290 units (SEC Form 4) (for withholding tax)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Technology Officer Carpenter Rick converted options into 2,507 shares and covered exercise/tax liability with 1,277 shares, increasing direct ownership by 4% to 32,148 units (SEC Form 4) (for tax liability)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Legal Officer Hansen Shannon Marie converted options into 3,014 shares and covered exercise/tax liability with 1,535 shares, increasing direct ownership by 5% to 31,650 units (SEC Form 4) to cover taxes4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- SECSEC Form 10-Q filed by Tandem Diabetes Care Inc.10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)
- SECTandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
- PRTandem Diabetes Care Announces Second Quarter 2026 Financial ResultsTandem Diabetes Care, Inc. (NASDAQ:TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in the U.S. Operating margin improved 800 basis points compared to second quarter 2025 Scaled pay-as-you-go reimbursement model resulting in 10% of U.S. sales through the pharmacy channel Second Quarter 2026 Strat
- PRTandem Diabetes Care Announces Upcoming Conference PresentationTandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuity’s 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time). The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology comp
- ANALYSTUBS resumed coverage on Tandem Diabetes Care with a new price targetUBS resumed coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $18.00
- INSIDEREVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 3,636 shares and covered exercise/tax liability with 1,926 shares, increasing direct ownership by 6% to 29,815 units (SEC Form 4) (tax withholding)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- PRTandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International MarketsCompatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2™ insulin pump with Control-IQ+TM automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor in five countries. This launch expands continuous glucose monitoring choice for t:slim X2 pump users in the United Kingdom, Switzerland, Sweden, Finland, and Italy. Tandem expects to add additional countries in 2026, including Belgium, the Netherlands, and Germany."People using AID want fle
- PRTandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6
- ANALYSTDeutsche Bank initiated coverage on Tandem Diabetes Care with a new price targetDeutsche Bank initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.50
- PRTandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During PregnancyTandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery (AID) systems in Europe. The t:slim X2 and Tandem Mobi insulin delivery systems running Control-IQ+ AID technology are now approved for use by people with type 1 diabetes during pregnancy and adults with type 2 diabetes. "These expanded indications underscore the strength of our portfolio and our commitment to bringing innovative diabetes technology to more people worldwide," said John Sheridan, president and chief executive officer. "By expanding access to our AID technology, we're broadening ou
- INSIDEREVP, Chief Strategy Officer Gasser Elizabeth Anne gifted 7,160 shares and received a gift of 7,160 shares, closing all direct ownership in the company (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT & CEO Sheridan John F4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Chief Strategy Officer Gasser Elizabeth Anne4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Operating Officer Kyrillos Jean-Claude4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Legal Officer Hansen Shannon Marie4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Admin. Officer Morrison Susan4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
TNDM FAQ
7 questionsWhat does Tandem Diabetes Care Inc. do?
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a...Where does TNDM stock trade?
Tandem Diabetes Care Inc. (TNDM) is listed on NASDAQ.What sector and industry is TNDM in?
Tandem Diabetes Care Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Tandem Diabetes Care Inc. go public?
Tandem Diabetes Care Inc. (TNDM) completed its IPO in 2013.What are analysts saying about TNDM?
Tandem Diabetes Care Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-08-21. Recent price targets range from $1550.00 to $3500.00.What companies are similar to TNDM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare TNDM side-by-side with any of them on Quantisnow.How can I track TNDM on Quantisnow?
Quantisnow aggregates Tandem Diabetes Care Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNDM to receive live email and push alerts on every new disclosure.